Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia.

Autor: Zhang R; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khare P; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Banerjee P; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Medical Physiology, College of Medicine, Texas A&M University Health Science Center, Bryan, TX, USA., Ivan C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Caris Life Sciences, Irving, TX, USA., Schneider S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA., Barbaglio F; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Clise-Dwyer K; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jensen VB; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thompson E; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mendoza M; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chiorazzi N; Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.; Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, NY, USA.; Departments of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Uniondale, NY, USA.; Northwell Health Cancer Institute, Lake Success, NY, USA., Chen SS; Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA., Yan XJ; Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ghia P; B cell neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.; Università Vita-Salute San Raffaele, Milan, Italy., Caligaris-Cappio F; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.; AIRC (Associazione Italiana per la Ricerca sul Cancro), 20123, Milan, Italy., Mendonsa R; Navan Technologies, Inc, San Carlos, CA, USA., Kasimsetty S; Navan Technologies, Inc, San Carlos, CA, USA., Swoboda R; Navan Technologies, Inc, San Carlos, CA, USA., Bayraktar R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gandhi V; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Calin GA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keating MJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bertilaccio MTS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. MSBertilaccio@mdanderson.org.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Oct 23; Vol. 14 (1), pp. 168. Date of Electronic Publication: 2024 Oct 23.

Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response.

Autor: Dragomir MP; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.; Department of Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Fuentes-Mattei E; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA., Winkle M; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Okubo K; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA., Bayraktar R; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Knutsen E; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.; Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway., Qdaisat A; Department of Emergency Medicine, The University of Texas MDACC, Houston, Texas, USA., Chen M; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Li Y; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.; Department of Breast Surgery, Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Science; Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China., Shimizu M; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Pang L; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Liu K; Department of Radiation Physics, The University of Texas MDACC, Houston, Texas, USA., Liu X; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA., Anfossi S; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Zhang H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.; Department of Pediatric Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China., Koch I; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Tran AM; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.; Baylor College of Medicine, Graduate School of Biomedical Sciences, Houston, Texas, USA., Mohapatra S; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Ton A; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Kaplan M; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, Texas, USA., Anderson MW; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Rothfuss SJ; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA., Silasi R; Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA., Keshari RS; Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA., Ferracin M; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Ivan C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA., Rodriguez-Aguayo C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.; Center for RNA Interference and Non-coding RNAs, The University of Texas MDACC, Houston, Texas, USA., Lopez-Berestein G; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA.; Center for RNA Interference and Non-coding RNAs, The University of Texas MDACC, Houston, Texas, USA., Georgescu C; Genes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma., Banerjee PP; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, Texas, USA., Basar R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, Texas, USA., Li Z; Department of Biostatistics, The University of Texas MDACC, Houston, Texas, USA., Horst D; Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany., Vasilescu C; Department of Surgery, Fundeni Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Bertilaccio MTS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, USA., Rezvani K; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, Texas, USA., Lupu F; Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA., Yeung SC; Department of Emergency Medicine, The University of Texas MDACC, Houston, Texas, USA., Calin GA; Department of Translational Molecular Pathology, The University of Texas MDACC, Houston, Texas, USA.; Center for RNA Interference and Non-coding RNAs, The University of Texas MDACC, Houston, Texas, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2023 Jul 17; Vol. 133 (14). Date of Electronic Publication: 2023 Jul 17.

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.

Autor: Aslan B; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kismali G; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Biochemistry, Ankara University Faculty of Veterinary Medicine, Ankara, Turkey., Iles LR; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Manyam GC; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ayres ML; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen LS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gagea M; Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bertilaccio MTS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda WG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gandhi V; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org.

Publikováno v: Blood cancer journal [Blood Cancer J] 2022 May 20; Vol. 12 (5), pp. 80. Date of Electronic Publication: 2022 May 20.